The value of #RWD for informing better trial designs, supporting regulatory decisions, and improving patient diversity is critical as we continue to close the gap between care and research. Neal Meropol, Flatiron's Head of Research Oncology, was recently interviewed on The Bio Report with Daniel Levine to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development. Tune in to learn how Flatiron Health is harnessing the power of RWD to reshape the landscape of oncology research and accelerate the development of new treatments. ▶️ https://lnkd.in/g7YvHNK3
Flatiron Health’s Post
More Relevant Posts
-
Many thanks to Daniel Levine for a great conversation on The Bio Report podcast about the many ways that #realworlddata can support evidence generation to benefit cancer patients, in particular recent approaches to enhancing trial representativeness by applying RWD to study design, and reducing patient and site burden by streamlining data collection needs. The closer we can integrate #clinicaltrials into routine care, the more likely that study results will be generalizable to ALL cancer patients.
The value of #RWD for informing better trial designs, supporting regulatory decisions, and improving patient diversity is critical as we continue to close the gap between care and research. Neal Meropol, Flatiron's Head of Research Oncology, was recently interviewed on The Bio Report with Daniel Levine to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development. Tune in to learn how Flatiron Health is harnessing the power of RWD to reshape the landscape of oncology research and accelerate the development of new treatments. ▶️ https://lnkd.in/g7YvHNK3
Reshaping Clinical Trial Designs with Real-World Data | The Bio Report
thebioreport.podbean.com
To view or add a comment, sign in
-
Did you know there’s more on Vivli than just clinical trial data? Find out more about what's available in our repository of nearly 7,000 studies, and how you can access data that will take your research further: https://lnkd.in/es33eG_d
Breast cancer research and data sharing – an interview with Dr. Ashley Hopkins
https://www.youtube.com/
To view or add a comment, sign in
-
The adaptation of emerging data and therapies into clinical practice is vital to improving patient outcomes. We support oncologists by connecting them with distinguished leaders, and mobilizing data around the globe. https://bit.ly/3sW5GT3
To view or add a comment, sign in
-
With major advances in the understanding of cancer, the cancer treatment landscape has evolved, resulting in significant changes in therapy and in turn the primary endpoints elected for cancer clinical trials. Experts emphasize the need for transparency when changing primary endpoints in oncology clinical trials.
Changing primary endpoints in clinical trials: proceed with caution
share.postbeyond.com
To view or add a comment, sign in
-
Effective and meaningful communication is at the heart of patient-centered care. Calling on patient organizations to share this new Patient-Friendly Biomarker Test Report Summary Template, and encourage its use among the medical community. More information about it here: https://bit.ly/4bRxRU1 Let us know if you have a partner who wants to pilot the tool in a clinical setting! #PatientCentricCare #BiomarkerTestReports
New tool for HCPs aims to decode complex results in precision oncology
precisionmedicine.synapseconnect.org
To view or add a comment, sign in
-
Don't miss the EMA/EORTC workshop 👉 How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? 📅 29 February https://europa.eu/!TVfryM How can you take part? ✍ In-person registration open until 15 January 💻 Online registration open until 16 February The event will explore the importance of patient-reported data in shaping regulatory decisions on cancer treatments, featuring expert speakers and an interactive discussion with industry, academia, regulatory agencies, health technology assessment bodies, healthcare professionals and patients. #cancerawareness #treatcancer #research
To view or add a comment, sign in
-
An important discussion to add to your February calendar 🗓️ #cancer #stakeholder #engagement
Don't miss the EMA/EORTC workshop 👉 How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? 📅 29 February https://europa.eu/!TVfryM How can you take part? ✍ In-person registration open until 15 January 💻 Online registration open until 16 February The event will explore the importance of patient-reported data in shaping regulatory decisions on cancer treatments, featuring expert speakers and an interactive discussion with industry, academia, regulatory agencies, health technology assessment bodies, healthcare professionals and patients. #cancerawareness #treatcancer #research
To view or add a comment, sign in
-
At Clinical Trials in Oncology’s West Coast conference, experts discussed strategies to address trial diversity. Technology was a major point of discussion, although patient experience must be central to how these advances are adopted. Get more insights into this discussion from Clinical Trials Arena and leave a comment to let us know what you think. https://ow.ly/9k8f50S92Ik #econsent #clinicaltrialdiversity #clinicalresearch
Tackling trial diversity in a biased clinical development landscape
clinicaltrialsarena.com
To view or add a comment, sign in
-
Don't miss the EMA/EORTC workshop 👉 How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? 📅 29 February https://europa.eu/!TVfryM The event will explore the importance of patient-reported data in shaping regulatory decisions on cancer treatments, featuring expert speakers and an interactive discussion with industry, academia, regulatory agencies, health technology assessment bodies, healthcare professionals and patients. #cancerawareness #treatcancer #research
To view or add a comment, sign in
-
Case Study: Unlocking Access with Innovation and Persistence We supported the launch of a revolutionary ovarian cancer treatment across England and Wales, benefiting both BRCA+ and BRCA- patients, navigating the complexities of the NICE STA process. Challenges: • Limited mature Overall Survival data, impacting cost-effectiveness demonstration. • Defining optimal market entry strategy amidst competitor presence. Find out how we overcame these hurdles and achieved: • CDF recommendation for full licensed indication at a commercially viable price. • Increased patient access to this life-saving treatment. https://lnkd.in/eqWJHVRb This case study showcases our commitment to overcoming market access hurdles for innovative treatments, ultimately improving patient outcomes. #OvarianCancer #HealthcareAccess #Innovation #PatientOutcomes
Case Study: Mature OS Data
pages.fiecon.com
To view or add a comment, sign in
75,943 followers